Denali Therapeutics (DNLI) Return on Sales (2018 - 2024)

Denali Therapeutics (DNLI) has 7 years of Return on Sales data on file, last reported at 3.36% in Q2 2024.

• On a quarterly basis, Return on Sales fell 336.0% year-over-year to 3.36% in Q2 2024; TTM through Jun 2024 was 3.36%, a 335.0% decrease from a year earlier, with the FY2023 full-year figure at 0.0%, up 3.0% from the prior year.
• Return on Sales for Q2 2024 stood at 3.36%, down from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for DNLI reached as high as 0.01% in Q4 2020 and fell as low as 10.92% in Q1 2020.
• Historically, Return on Sales has averaged 0.89% across 5 years, with a median of 0.05% in 2021.
• Across the five-year window, Return on Sales slumped 1083 bps in 2020 and jumped 1083 bps in 2021, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2020, then sank by 300 bps to 0.02% in 2021, then plunged by 538 bps to 0.1% in 2022, then jumped by 95 bps to 0.0% in 2023, then slumped by 74756 bps to 3.36% in 2024.
• Per Business Quant data, the three most recent Return on Sales figures were 3.36% in Q2 2024, 0.0% in Q1 2024, and 0.0% in Q4 2023.